Who
Reuven Yeganeh
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, BiomX; Chief Executive Officer, T3 Defense.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $16.5M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 16 Dec 2024
- Last trade
- 17 Mar 2026
- Last filed
- 18 Mar 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Mar 2026filed 18 Mar 2026 | BiomXBiotechnology | SEC FORM 4 Code C | $1.1M530,000 at $2.00 | filing |
| 17 Mar 2026filed 18 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,060 at $0.00 | filing |
| 17 Mar 2026filed 18 Mar 2026 | BiomXBiotechnology | SEC FORM 4 Sold | $2.6M530,000 at $5.00 | filing |
| 17 Mar 2026filed 18 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,060 at $0.00 | filing |
| 17 Mar 2026filed 18 Mar 2026 | BiomXBiotechnology | SEC FORM 4 Code C | $1.1M530,000 at $2.00 | filing |
| 17 Mar 2026filed 18 Mar 2026 | BiomXBiotechnology | SEC FORM 4 Sold | $2.6M530,000 at $5.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXBiotechnology | SEC FORM 4 Code C | $900K450,000 at $2.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXBiotechnology | SEC FORM 4 Sold | $2.3M450,000 at $5.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code C | —900 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code S | $6.5M1,300,000 at $5.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code S | $10.5M2,000,000 at $5.24 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code S | $8.1M1,700,000 at $4.76 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code C | —900 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code S | $6.5M1,300,000 at $5.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code S | $10.5M2,000,000 at $5.24 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXBiotechnology | SEC FORM 4 Code C | $900K450,000 at $2.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXBiotechnology | SEC FORM 4 Sold | $2.3M450,000 at $5.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code S | $8.1M1,700,000 at $4.76 | filing |
| 13 Mar 2026filed 13 Mar 2026 | BiomXBiotechnology | SEC FORM 4 Code C | $740K370,000 at $2.00 | filing |
| 13 Mar 2026filed 13 Mar 2026 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code C | —740 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.